What we do here
changes lives everywhere.

Anthony G. Letai, MD, PhD; John K., patient; Elyahs J., patient; Jacqueline Garcia, MD

Identifying BCL-2 as a protein cancer cells use to prevent self-destruction leads to the BCL-2 inhibitor venetoclax, which has become a powerful agent in the fight against CLL and AML.

Pasi A. Jänne, MD, PhD; Ryan F., patient

Identifying the EGFR mutation leads to the first broad application of precision medicine in lung cancer – which is paving the way for other active targeted lung cancer therapies.

F. Stephen Hodi, Jr., MD; Naftali I., patient; Gordon J. Freeman, PhD

Combining treatments of the PD-L1 and CTLA-4 pathways creates a “double assault” that is effective for melanoma, kidney and other cancers.

William G. Kaelin Jr., MD; Chuck S., patient

Understanding how cancer hijacks the body’s oxygen-sensing system leads to new therapies for kidney cancer, heart disease and more.